Piper Jaffray Cos. reiterated their buy rating on shares of Voyager Therapeutics Inc. (NASDAQ:VYGR) in a research note issued to investors on Sunday morning. They currently have a $37.00 target price on the stock.

Other equities analysts have also issued reports about the company. Zacks Investment Research raised Voyager Therapeutics from a hold rating to a buy rating and set a $13.00 target price on the stock in a research report on Wednesday, October 12th. Cowen and Company reaffirmed a buy rating on shares of Voyager Therapeutics in a research report on Thursday. Finally, Wedbush reaffirmed an outperform rating and set a $36.00 target price on shares of Voyager Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Voyager Therapeutics currently has a consensus rating of Buy and a consensus target price of $26.80.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Shares of Voyager Therapeutics (NASDAQ:VYGR) opened at 12.24 on Friday. The firm’s market capitalization is $327.15 million. Voyager Therapeutics has a 1-year low of $8.12 and a 1-year high of $30.54. The firm has a 50-day moving average of $12.15 and a 200-day moving average of $12.92.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Thursday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.03. Voyager Therapeutics had a negative return on equity of 20.15% and a negative net margin of 195.31%. On average, equities research analysts anticipate that Voyager Therapeutics will post ($1.48) EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. TFS Capital LLC bought a new stake in shares of Voyager Therapeutics during the second quarter valued at about $324,000. FMR LLC increased its stake in shares of Voyager Therapeutics by 1.8% in the second quarter. FMR LLC now owns 3,973,851 shares of the company’s stock valued at $43,673,000 after buying an additional 71,503 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of Voyager Therapeutics by 195.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 92,484 shares of the company’s stock valued at $1,016,000 after buying an additional 61,168 shares during the period. BlackRock Group LTD bought a new stake in shares of Voyager Therapeutics during the second quarter valued at about $158,000. Finally, BlackRock Fund Advisors increased its stake in shares of Voyager Therapeutics by 106.8% in the second quarter. BlackRock Fund Advisors now owns 302,971 shares of the company’s stock valued at $3,330,000 after buying an additional 156,443 shares during the period. Institutional investors and hedge funds own 39.65% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

5 Day Chart for NASDAQ:VYGR

Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.